Background: Although adjuvant chemotherapy improves survival in patients with completely resected NSCLC, it is also associated with potentially disabling or lethal adverse events. Because there is limited information on the early mortality among patients undergoing adjuvant chemotherapy, we used the National Cancer Database to calculate the percentage of deaths within the first 6 months of starting chemotherapy.
Introduction
Lung cancer is both the most frequently diagnosed and the most frequent cause of cancer death worldwide, with an estimated approximately 1,825,000 cases diagnosed and 1,590,000 deaths in 2012 according to the GLOBOCAN. 1 In the United States, the American Cancer *Corresponding author.
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Society estimates 225,500 new cases and 155,870 deaths from lung cancer, making it the second most frequently diagnosed and the most frequent cause of cancer death. 2 Among patients with lung cancer, approximately 85% have one of the NSCLC histologic types. 3 Surgery represents the primary treatment modality for patients with early-stage NSCLC, providing the best probability of cure. Nevertheless, despite surgery with curative intent, tumor relapse eventually develops in a large percentage of patients, with 5-year overall survival (OS) ranging from 73% in pathologic stage IA to 24% in stage IIIA. 4 Because most relapses occur at distant sites, chemotherapy has been used in an attempt to eradicate micrometastatic disease. Several trials have shown a benefit from adjuvant cisplatin-based chemotherapy doublets in patients with completely resected NSCLC. [5] [6] [7] In a meta-analysis including 4751 patients accrued into 18 trials comparing surgery plus platinum-based adjuvant chemotherapy with surgery alone, there were absolute improvements in 5-year OS from 55% to 60% in stage IB, 40% to 45% in stage II, and 30% to 35% in stage III NSCLC. 8 In the Lung Adjuvant Cisplatin Evaluation (LACE) pooled analysis of five studies, the absolute 5-year OS from adjuvant cisplatin-based chemotherapy doublets was 5.4% (hazard ratio ¼ 0.89, 95% confidence interval [CI] 0.82-0.96, p ¼ 0.005). 9 The use of chemotherapy was also associated with a 5.8% absolute improvement in the disease-free survival (hazard ratio ¼ 0.84, 95% CI: 0.78-0.91, p < 0.001). Adjuvant platinumbased chemotherapy is currently recommended as the standard of care for patients with resected stage II and IIIA NSCLC, with a likely role in stage IB. [10] [11] [12] [13] Adjuvant chemotherapy, particularly with the recommended cisplatin-based regimens however, may be associated with significant toxicities. In the LACE pooled analysis, 34% of patients could not complete the planned number of chemotherapy cycles on account of toxicity. 9 Grade 3 to 4 adverse events developed in 66% of the 2281 patients randomized to adjuvant chemotherapy, including grade 4 adverse events in 32% of them. Furthermore, during the first 6 months, there was a higher frequency of non-lung cancer-related deaths in the chemotherapy group, with a 2% decrease in OS compared with observation (96.6% versus 98.6%). Among the 103 non-cancer-related deaths, 29 occurred in the observation group and 74 in the chemotherapy group. Pulmonary or cardiovascular events were the most frequent cause of death in the first 6 months, occurring in 40 patients (1.8%), whereas chemotherapyrelated deaths were seen in 19 patients (0.9%).
To further explore the prevalence of early mortality in this setting, we used the National Cancer Database (NCDB) to identify patients with stage IB to IIIA patients receiving adjuvant chemotherapy and evaluate for patient and tumor factors that were independently associated with a 6-month mortality after initiation of chemotherapy.
Methods
The NCDB is a joint program of the American College of Surgeons and the American Cancer Society; it was established in 1989 and includes approximately 70% of cancer cases in United States. 14 The NCDB participant user file was queried for patients with NSCLC who underwent a surgical procedure followed by adjuvant chemotherapy between 2004 and 2012, the former representing the first year in which chemotherapy was established as a standard therapy for patients with resected stage I to IIIA NSCLC and the latter as the penultimate year available in the database at the time of the study, to allow a minimum follow-up of 12 months.
Eligibility criteria included patient age 18 or older and pathologic stage IB to IIIA NSCLC treated with at least wedge resection and multiagent adjuvant chemotherapy that was started within 21 to 120 days after the surgery. Patients with positive or unknown margins, local ablation, or unknown surgical procedure and treatment with adjuvant radiation therapy were excluded. NSCLC histologic types according to the International Classification of Diseases for Oncology, Third Edition, included adenocarcinoma (8140-8147, 8260, 8310, 8323, 8490, and 8570-8576), squamous cell carcinoma (8052, 8070-8076, and 8083-8084), large cell carcinoma (8012 and 8014), adenosquamous (8560), and NSCLC not otherwise specified (8046).
Patient demographics and characteristics included age, sex, race, histologic type, pathologic stage, type of surgery, Charles-Deyo comorbidity score, insurance, education, population type, length of postoperative stay, and readmission within 30 days from surgical procedure. Age groups were divided into younger than 50, 51 to 60, 61 to 70, 70 to 80, and older than 80 years. The histologic division into squamous and nonsquamous type was based on the current criteria for selection of adjuvant chemotherapy regimens. The length of stay was divided into two groups according to the median time from surgery to discharge.
The database provides the number of days from diagnosis to initiation of each treatment modality, including surgery, radiation therapy, and chemotherapy, as well as time from diagnosis to death. The time from surgery to initiation of adjuvant chemotherapy was calculated as time from diagnosis to chemotherapy minus time from diagnosis to surgery, whereas the time from initiation of chemotherapy to death was calculated as time from diagnosis to death minus time from diagnosis to chemotherapy. Early mortalities were defined as occurring within 6 months after the initiation of chemotherapy. Patients with censoring before 6 months were evaluated for the cumulative mortality only. Categorical variables were compared by using chi-square analysis. A p value less than 0.05 was considered significant.
Multivariable logistic regression was performed to identify variables independently associated with mortality 6 months after the initiation of adjuvant chemotherapy. Criteria for entry into the logistic regression model included p value less than 0.05 on univariate analysis. All analyses were performed in SPSS, version 24 (IBM Corporation, Armonk, NY).
Results
From a total of 1,039,989 patients in the NCDB with NSCLC that was diagnosed during the study period, 19,691 patients met the inclusion criteria and were included in the overall mortality analysis (Fig. 1) . Among those, 19,398 had data on 6-month survival and were evaluated for the primary study objective. The median age was 65 (interquartile range [IQR] 58-71), and the median length of stay postoperatively was 6 days (IQR 4-8). More than half of the patients were male (52.5%), and most had the nonsquamous histologic type of NSCLC (60.9%), had pathologic stage II disease (48.9%), and had undergone lobectomy (82.3%).
The median follow-up from the time of diagnosis for all patients was 38.3 months (IQR 22.2-65.1) . The percentages of patients who died 1, 2, 3, 4, 5, and 6 months from initiation of adjuvant chemotherapy were 0.7% (128 events), 1.3% (258 events), 1.9% (365 events), 2.6% (501 events), 3.2% (630 events), and 4.1% (799 events), respectively (Fig. 2) . The mortality rates 6 months after the start of adjuvant chemotherapy for each age group (50, 51-60, 61-70, 71-80, and >80 years) were 2.6%, 3.1%, 4.1%, 5.3%, and 7.6% respectively (Fig. 3) comorbidity score, length of postoperative stay longer than 6 days, 30-day readmission after surgery, nonprivate insurance, and residence in lower-education and lower-income zip codes (Table 1) . Patients who had a Charles-Deyo comorbidity score of 2 or higher and were age 70 or older had the highest rate for early mortality at 14.6%. Factors independently associated with an increased likelihood of 6-month mortality on multivariable analysis included increasing age, male sex, increasing Charles-Deyo comorbidity score, pneumonectomy, higher pathologic stage, length of postoperative stay longer than 6 days, and having a 30-day readmission (Table 2) .
Discussion
Adjuvant chemotherapy improves the survival in patients with completely resected stage II and III NSCLC, with a likely benefit in subsets of patients with stage IB. Nevertheless, it is also associated with increased early mortality. In a large study-level meta-analysis that included 6430 patients from 16 randomized clinical trials evaluating the role of cisplatin-based adjuvant chemotherapy, the incidences of deaths unrelated to lung cancer for the 3211 patients undergoing chemotherapy and 3219 patients assigned to the control arm were 9.3% and 7.3%, respectively (relative risk ¼ 1.3. 95% CI: 1.1-1.53, p ¼ 0.002). 15 In our study, the 6-month mortality rate increased with age, surpassing 5% in patients older than 70 years. Elderly patients are frequently excluded or underrepresented in clinical trials. Among the 4584 patients from the five studies included in the LACE analysis, only 414 (0.9%) were 70 years or older. 16 Compared with younger patients, elderly patients received a significantly lower dose of chemotherapy; in particular, a lower percentage of patients recieve all the planned cycles of adjuvant chemotherapy (58% versus 77% [p < 0.001]) and a dose of at least 250 mg/m 2 of cisplatin (42% versus 64% [p < 0.001]). Nevertheless, although there was a survival benefit from adjuvant therapy in the elderly population, the total number of non-lung cancerrelated deaths increased from 12% in patients younger than 65 years to 22% in elderly patients. Because there were only 61 patients (1.3% of the total) older than 75 years, this age group was not evaluated separately in the study. In a subset analysis of the elderly patients treated in the JBR.10 trial (in which elderly was defined as older than 65 years), adjuvant chemotherapy with cisplatin plus vinorelbine was associated with acceptable toxicity and improved survival compared with observation. 17 However, in an exploratory analysis, there were 15 deaths from nonmalignant causes among the 71 elderly patients (21.1%), including in eight out of 16 patients older than 75 (50%). Although the outcomes in the small number of patients in the latter patient population should be interpreted with caution, the high mortality from non-lung cancer raises concern over the use of adjuvant chemotherapy in this age group. Because adjuvant chemotherapy is not generally used in octogenarians, there were only 392 patients included in our study. Nevertheless, the mortality rates at 6 and 12 months of 7.6% and 16.1%, respectively, suggest that adjuvant chemotherapy in this group should be used only in carefully selected patients.
Our study showed that in addition to being associated with age, early mortality rates were also increased in patients with a more complicated postoperative course, causing either a delayed length of stay or 30-day readmission. In a large study that included 129,893 patients from the NCDB undergoing a surgical procedure for stage I to III NSCLC between 1998 and 2010, there were 5624 patients (4.3%) unexpectedly readmitted within 30 days. 18 Readmissions within 30 days were more frequent in older patients and those undergoing pneumonectomy, and they were associated with increased mortality at 90 days (7% versus 3.3% [p < 0.001]) and shorter median survival (38.9 months versus 54.1 months [p < 0.001]). A similar finding was observed in a Surveillance Epidemiology and End Results-Medicare registry, in which the 30-day postoperative readmission rate for the 11,432 evaluated patients was 12.8% and was associated with a sixfold increase in the 90-day mortality (14.4% versus 2.5% [p < 0.01]). 19 Prolonged length of stay has also been previously associated with increased mortality. In a study using data on 4979 patients in the Society of Thoracic Surgeons General Thoracic Surgery Database who were treated with lobectomy, prolonged length of stay, defined as lasting more 14 days, was observed in 351 patients (7%) and associated with higher mortality than was shorter length of stay (10.8% versus 0.7% [p < 0.0001]). 20 Our study showed that increased postoperative length of stay, in addition to the effects on surgical mortality, was also associated with increased 6-month mortality among patients who were eventually discharged and underwent adjuvant chemotherapy. There are several limitations to our data, including the retrospective nature of the study and lack of information on both the chemotherapy regimens used and the number of cycles administered. There are also no data on the staging procedures, Eastern Cooperative Oncology Group performance status at the start of chemotherapy, specific comorbidities, specific postoperative complications, and cause of death. Nevertheless, the NCDB allows the evaluation of subsets of patients who are often underrepresented or not included in clinical trials.
In conclusion, this analysis found that there are subsets of patients with a high 6-month mortality after starting to receive adjuvant chemotherapy. Although the decisions on the treatment of patients with NSCLC are based on results from randomized clinical trials, practitioners should be cautious about the extrapolation of these data into the general patient population, as the patients eligible for the clinical trials are preselected on the basis of performance status, comorbidities, and organ function and are not representative of all patients seen in practice. The increased mortality risk in patients who are older than 70 and have a high comorbidity score and a more complicated postoperative course appears intuitive and should be taken into account before the decision on the use of chemotherapy. Early mortality was particularly high in patients older than 80 years, for whom the benefit from adjuvant chemotherapy has not been established, indicating that good judgment and careful selection should be applied.
